Carboplatin Clinical Trials
339 recruitingDrug
Phase 2216Phase 391Phase 171Early Phase 14Not Applicable4Phase 43
Showing 1–20 of 339 trials
Recruiting
Phase 3
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Lung Non-Small Cell Carcinoma+3 more
National Cancer Institute (NCI)1,210 enrolled1151 locationsNCT04267848
Recruiting
Phase 3
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
GlioblastomaGBMRecurrent Glioblastoma
CarThera560 enrolled50 locationsNCT05902169
Recruiting
Phase 3
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Endometrial CarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Dedifferentiated Carcinoma+5 more
National Cancer Institute (NCI)360 enrolled409 locationsNCT05256225
Recruiting
Phase 3
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Stage IIIB Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8+1 more
National Cancer Institute (NCI)304 enrolled322 locationsNCT06096844
Recruiting
Phase 2
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Recurrent Head and Neck Squamous Cell CarcinomaRecurrent Oropharyngeal Squamous Cell CarcinomaRecurrent Hypopharyngeal Squamous Cell Carcinoma+2 more
National Cancer Institute (NCI)188 enrolled178 locationsNCT04671667
Recruiting
Phase 3
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Ovarian NeoplasmsNeoplasm MetastasisFallopian Tube Neoplasms+1 more
Eli Lilly and Company1,630 enrolled266 locationsNCT07213804
Recruiting
Phase 3
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Stage IIIA Cervical Cancer FIGO 2018Stage IIIB Cervical Cancer FIGO 2018Locally Advanced Cervical Adenocarcinoma+5 more
National Cancer Institute (NCI)336 enrolled296 locationsNCT07061977
Recruiting
Phase 2
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
Locally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm
National Cancer Institute (NCI)115 enrolled1 locationNCT03907475
Recruiting
Phase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Low-grade GliomaLow Grade AstrocytomaWHO Grade 2 Glioma+3 more
National Cancer Institute (NCI)170 enrolled132 locationsNCT04166409
Recruiting
Phase 1Phase 2
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Ovarian CancerEndometrial CancerLung Adenocarcinoma+1 more
AstraZeneca602 enrolled60 locationsNCT05797168
Recruiting
Phase 1
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
Gastroesophageal Junction AdenocarcinomaClinical Stage II Esophageal Adenocarcinoma AJCC v8Clinical Stage III Esophageal Adenocarcinoma AJCC v8+10 more
M.D. Anderson Cancer Center24 enrolled1 locationNCT04615013
Recruiting
Phase 1
A Study of ASP1002 in Adults for Treatment of Solid Tumors
Advanced Solid Tumors
Astellas Pharma Global Development, Inc.798 enrolled15 locationsNCT05719558
Recruiting
Phase 2
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
Ovarian Cancer
AbbVie400 enrolled78 locationsNCT07059845
Recruiting
Phase 2
Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
Peritoneal Malignant Mesothelioma
National Cancer Institute (NCI)66 enrolled40 locationsNCT05001880
Recruiting
Phase 1Phase 2
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Non-Small-Cell Lung Carcinoma
AbbVie252 enrolled112 locationsNCT06772623
Recruiting
Phase 2
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Stage IV Nasopharyngeal Carcinoma AJCC v8Metastatic Nasopharyngeal CarcinomaRecurrent Nasopharyngeal Carcinoma
National Cancer Institute (NCI)156 enrolled88 locationsNCT06029270
Recruiting
Phase 2
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
AstraZeneca630 enrolled97 locationsNCT05061550
Recruiting
Phase 3
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Carcinoma, Non-Small Cell Lung
Mirati Therapeutics Inc.630 enrolled351 locationsNCT06875310
Recruiting
Phase 2
Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab
Lung Cancer, Non-squamous, Non-small Cell
Boehringer Ingelheim60 enrolled17 locationsNCT07486817
Recruiting
Phase 3
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
Extrapulmonary Neuroendocrine Cancer (epNEC)
Boehringer Ingelheim390 enrolled165 locationsNCT07544654